Cell Therapeutics Europe

CTI BioPharma, formerly known as Cell Therapeutics, is a commercial-stage biopharmaceutical company specializing in the development and acquisition of novel therapies for blood-related cancers. The company's flagship product, Vonjo (pacritinib), is an oral kinase inhibitor approved by the FDA for the treatment of adult patients with intermediate or high-risk primary or secondary myelofibrosis who have severe thrombocytopenia. CTI BioPharma also developed Pixuvri (pixantrone), which received conditional marketing authorization in the European Union for the treatment of multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. In June 2023, the company was acquired by Swedish Orphan Biovitrum (Sobi) for approximately $1.7 billion, integrating its hematology portfolio into Sobi's global operations. The company's research focuses on targeting specific signaling pathways, including JAK2, IRAK1, and FLT3, to address unmet needs in hematologic malignancies.